Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
Another gene therapy startup looks primed for an IPO. Orchard Therapeutics has just landed another $150 million to help drive forward a group of gene therapies it bought from British pharma... Read more »
[Updated, 8/13/18, see below] The FDA has approved a new treatment for Fabry disease, a decision that represents the end of a winding, more than decade-long saga for the... Read more »
[Updated at 4:08 pm ET, see below] Alnylam Pharmaceuticals made history this afternoon.
Two imminent FDA rulings on two separate drugs aren’t just noteworthy for the patients they’ll help, but the long and winding road their developers have taken to get to this point.... Read more »
A new biotech has debuted today aiming to make a variety of treatments for deadly liver diseases. The startup, Ambys Medicines, has formed an unusual, broad alliance with Takeda.
Some early,... Read more »
Being a newcomer can mean a few different things: being new to the area (or newly back after being away) or new to an industry. The finalists for Xconomy’s Newcomer Award... Read more »
Regeneron Pharmaceuticals and Bluebird Bio have struck a wide-ranging partnership to broaden the reach of their respective cancer immunotherapy work, inking a deal to develop multiple cell therapies together.
Regeneron (NASDAQ:... Read more »
[Updated, 8/6/18, see below] By next weekend, the FDA could for the first time approve a medicine that uses a biological trick that was only discovered two decades ago:... Read more »
Our profiles of the finalists for this year’s Xconomy Awards roll on today with a look at the nominees for the Contrarian award.
These finalists have been nominated for different reasons.... Read more »
The devil is in the details, and key clinical trial results made that abundantly clear this week. Eisai and partner Biogen released the highly anticipated details of an Alzheimer’s disease study... Read more »
In June, Jennifer Petter, the founder and chief scientific officer of biotech startup Arrakis Therapeutics, got an e-mail from a stranger. His name was Ramsey Johnson, a biotech veteran who works... Read more »
Sangamo Biosciences has acquired French biotech TxCell, adding an experimental technology with the potential to treat autoimmune diseases with cell therapy.
After nearly two years of all smoke, no fire around President Trump’s promise to curtail drug prices, there’s finally some glimmer of action. Pfizer said last week it would halt its... Read more »
Just weeks ago, the FDA approved the first ever medicine made from a derivative of marijuana, a drug from GW Pharmaceuticals for a rare form of epilepsy. Yet competition already looms... Read more »
If you’re running a privately held biotech, the time to go public is now. Clinical data already in hand or not, biotechs have charged to Wall Street at a record pace... Read more »
The race to treat anemia with a pill, not an injectable biologic, just took a new turn.
Over the past few years, a new class of drugs known as “PARP” inhibitors has begun to change how ovarian cancer is treated. Data released by AstraZeneca and partner Merck this... Read more »
Be your own biotech cluster, not a Boston redux. Accelerate the momentum that’s already begun, don’t let it fizzle. And above all, be fearless entrepreneurs. You’ll need to be if New... Read more »
Cancer immunotherapy combinations continue to chalk up wins against lung cancer. For the first time, an immunotherapy-chemotherapy combination has succeeded in a late-stage study of patients with small cell lung cancer... Read more »
September 5, 2018
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.